NCT04585815 2026-01-09Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)PfizerPhase 1/2 Terminated34 enrolled 44 charts
NCT03915951 2025-11-17An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerPfizerPhase 2 Completed98 enrolled 18 charts 1 FDA